Literature DB >> 12893396

Fecal occult blood testing in a general medical clinic: comparison between guaiac-based and immunochemical-based tests.

Cynthia W Ko1, Jason A Dominitz, Toan D Nguyen.   

Abstract

PURPOSE: Guaiac-based fecal occult blood tests are limited by poor patient compliance, and low sensitivity, specificity, and positive predictive value. Newer immunochemical-based tests are designed to improve accuracy and patient compliance. We compared patient compliance and the test characteristics of these two types of tests.
METHODS: The laboratory outcomes associated with use of different fecal occult blood tests were examined in a Veterans Affairs-based general medicine clinic that was divided into two firms with similar patient and provider characteristics. Tests were ordered for colorectal cancer screening or for symptom evaluation. Patients were given one of the two tests depending on their firm. The completion and positivity rates, time to test completion, completion of diagnostic follow-up, and positive predictive values were compared.
RESULTS: The percentage of returned test cards was similar between the two groups (47% [1369/2964] for guaiac-based tests vs. 48% [1410/2965] for immunochemical-based tests) as was the positivity rate (9.0% [122/1396] and [128/1410] for both groups). In patients with positive tests who underwent further colon evaluation, the proportion with adenomas was similar between groups (59% [38/64] vs. 58% [40/69]). However, 17% (12/69) with a positive immunochemical-based test had an adenoma >1 cm or a colorectal malignancy, versus 30% (19/64) for guaiac-based tests (P = 0.09).
CONCLUSION: Overall, immunochemical-based and guaiac-based fecal occult blood tests had comparable performance. However, although immunochemical-based testing is reported to be easier for patients than guaiac-based testing, we found that patients were no more likely to return cards for analysis. The similar positive predictive value and additional cost of immunochemical-based tests call into question their utility in general practice.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12893396     DOI: 10.1016/s0002-9343(03)00294-8

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  16 in total

1.  Systems of support to increase colorectal cancer screening and follow-up rates (SOS): design, challenges, and baseline characteristics of trial participants.

Authors:  Beverly B Green; C Y Wang; Kathryn Horner; Sheryl Catz; Richard T Meenan; Sally W Vernon; David Carrell; Jessica Chubak; Cynthia Ko; Sharon Laing; Andy Bogart
Journal:  Contemp Clin Trials       Date:  2010-07-30       Impact factor: 2.226

2.  Randomized controlled trial of the impact of intensive patient education on compliance with fecal occult blood testing.

Authors:  Charlene L Stokamer; Craig T Tenner; Jhuma Chaudhuri; Eva Vazquez; Edmund J Bini
Journal:  J Gen Intern Med       Date:  2005-03       Impact factor: 5.128

3.  Cost-effectiveness of colorectal cancer screening - an overview.

Authors:  Iris Lansdorp-Vogelaar; Amy B Knudsen; Hermann Brenner
Journal:  Best Pract Res Clin Gastroenterol       Date:  2010-08       Impact factor: 3.043

4.  The compliance rate for the second diagnostic evaluation after a positive fecal occult blood test: A systematic review and meta-analysis.

Authors:  Rachel Gingold-Belfer; Haim Leibovitzh; Doron Boltin; Nidal Issa; Tsachi Tsadok Perets; Ram Dickman; Yaron Niv
Journal:  United European Gastroenterol J       Date:  2019-02-06       Impact factor: 4.623

5.  Fecal occult blood test and gastrointestinal parasitic infection.

Authors:  Majed H Wakid
Journal:  J Parasitol Res       Date:  2010-07-26

6.  Detection of colorectal cancer in symptomatic outpatients without visible rectal bleeding: Validity of the fecal occult blood test.

Authors:  Niels Christian Bjerregaard; Anders Tøttrup; Henrik Toft Sørensen; Søren Laurberg
Journal:  Clin Epidemiol       Date:  2009-08-09       Impact factor: 4.790

7.  Reasons patients with a positive fecal occult blood test result do not undergo complete diagnostic evaluation.

Authors:  Masahito Jimbo; Ronald E Myers; Birgit Meyer; Terry Hyslop; James Cocroft; Barbara J Turner; David S Weinberg
Journal:  Ann Fam Med       Date:  2009 Jan-Feb       Impact factor: 5.166

8.  Randomized study comparing two regimens of oral sodium phosphates solution versus low-dose polyethylene glycol and bisacodyl.

Authors:  Pramod Malik; David H Balaban; William O Thompson; Deborah J B Galt
Journal:  Dig Dis Sci       Date:  2008-08-19       Impact factor: 3.199

9.  Improvement in the diagnostic evaluation of a positive fecal occult blood test in an integrated health care organization.

Authors:  Diana L Miglioretti; Carolyn M Rutter; Susan Carol Bradford; Ann G Zauber; Larry G Kessler; Eric J Feuer; David C Grossman
Journal:  Med Care       Date:  2008-09       Impact factor: 2.983

10.  As tests evolve and costs of cancer care rise: reappraising stool-based screening for colorectal neoplasia.

Authors:  M Parekh; A M Fendrick; U Ladabaum
Journal:  Aliment Pharmacol Ther       Date:  2008-01-29       Impact factor: 8.171

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.